EFFECTS OF METABOLIC PHARMACOTHERAPY IN REAL WORLD PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

被引：0
|
作者：
Eghbali, Shabnam [1 ]
Newberry, Carolyn [2 ]
Yeung, Michele [3 ]
Sharaiha, Reem [2 ]
Kumar, Sonal [2 ]
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Weill Cornell Med, Gastroenterol & Hepatol, New York, NY USA
[3] Weill Cornell Med, Endocrinol Diabet & Metab, New York, NY USA
来源：
HEPATOLOGY | 2022年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2624
引用
收藏
页码：S847 / S847
页数：1
相关论文
共 50 条
  • [31] Long term outcomes of non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD)
    Younossi, Zobair
    Paik, James
    Younossi, Issah
    Golabi, Pegah
    Harring, Michael
    Henry, Linda
    JOURNAL OF HEPATOLOGY, 2022, 77 : S155 - S156
  • [32] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    不详
    GASTROENTEROLOGE, 2021, 16 (05): : 386 - 386
  • [33] A lipidomic analysis of non-alcoholic fatty liver disease (NAFLD)
    Puri, P.
    Baillie, R. A.
    Wiest, M.
    Mirshahi, F.
    Sanyal, A. J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S260 - S261
  • [34] Is visfatin a protective adipokine in patients with non-alcoholic fatty liver disease (NAFLD)?
    Jarrar, Mohammed
    Elariny, Hazem A.
    Collantes, Rochelle S.
    Nugent, Clare
    Fang, Yun
    Stepanova, Maria
    Kopparti, Nirupama
    Goodman, Zachary D.
    Chandhoke, Vikas
    Baranova, Ancha
    Younossi, Zobair M.
    GASTROENTEROLOGY, 2007, 132 (04) : A819 - A820
  • [35] Cytokines and oxidative stress in patients with non-alcoholic fatty liver disease (NAFLD)
    Kumar, A.
    Kumar, R.
    Madan, K.
    Prakash, S.
    Sreenivas, V.
    Acharya, S. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A100 - A100
  • [36] Long Term Mortality of Patients with Non-alcoholic Fatty Liver Disease (NAFLD)
    Golabi, Pegah
    Otgonsuren, Munkhzul
    Arsalla, Aimal
    Erario, Madeline
    Srishord, Manirath
    Younossi, Zobair M.
    HEPATOLOGY, 2016, 64 : 529A - 530A
  • [37] Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
    Tripodi, Armando
    Lombardi, Rosa
    Primignani, Massimo
    La Mura, Vincenzo
    Peyvandi, Flora
    Fracanzani, Anna L.
    BIOMEDICINES, 2022, 10 (02)
  • [38] The role of bacterial overgrowth in patients with non-alcoholic fatty liver disease (NAFLD)
    Treiber, Gerhard
    Weigt, Jochen
    Kolfenbach, Sven
    Leodolter, Andreas
    Malfertheiner, Peter
    GASTROENTEROLOGY, 2006, 130 (04) : A823 - A823
  • [39] Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
    Kosmalski, Marcin
    Drzewoski, Jozef
    Szymczak-Pajor, Izabela
    Zieleniak, Andrzej
    Mikolajczyk-Solinska, Melania
    Kasznicki, Jacek
    Sliwinska, Agnieszka
    BIOMEDICINES, 2022, 10 (09)
  • [40] Antiepileptic drugs and non-alcoholic fatty liver disease (NAFLD)
    Waldmann, M
    Sturm, W
    Naser, A
    Unterberger, I
    Trinka, E
    Bauer, G
    Lechleitner, M
    Luef, G
    EPILEPSIA, 2004, 45 : 161 - 162
12345